Nivetha Ramesh Babu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nivetha Ramesh Babu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Alaina Lewis
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
11 shared publications - Alexander B. Saltzman
Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX, USA
11 shared publications - Amritha Nair
Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas
11 shared publications - Anna Malovannaya
Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX, USA
11 shared publications - Beom-Jun Kim
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
11 shared publications - Bing Zhang
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA
11 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Table S1: PDX proteogenomic data (related to Figure 2).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Table S1: PDX proteogenomic data (related to Figure 2).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S6: PTPN12-deficient primary TNBC are sensitive to taxane chemotherapy (related to Figure 6).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S6: PTPN12-deficient primary TNBC are sensitive to taxane chemotherapy (related to Figure 6).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S1: Integration of proteogenomics and functional genetics to reveal novel vulnerabilities in TNBC (related to Figure 1).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S1: Integration of proteogenomics and functional genetics to reveal novel vulnerabilities in TNBC (related to Figure 1).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S4: PTPN12 deficiency causes aberrant degradation of APCFZR1 substrates (related to Figure 4).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S4: PTPN12 deficiency causes aberrant degradation of APCFZR1 substrates (related to Figure 4).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S2: PTPN12-deficient models exhibit downregulation of cell cycle and mitotic pathways (related to Figure 2).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S2: PTPN12-deficient models exhibit downregulation of cell cycle and mitotic pathways (related to Figure 2).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Table S4: Integrated GSEA analysis (related to Figure 3).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Table S4: Integrated GSEA analysis (related to Figure 3).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Table S3: PTPN12-selective growth modifiers (related to Figure 3).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Table S3: PTPN12-selective growth modifiers (related to Figure 3).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S5: PTPN12-deficient cells exhibit mitotic defects dependent on APCFZR1 hyperactivation (related to Figure 5).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S5: PTPN12-deficient cells exhibit mitotic defects dependent on APCFZR1 hyperactivation (related to Figure 5).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S3: PTPN12-deficient cells are vulnerable to perturbation of mitotic regulators (related to Figure 3).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Figure S3: PTPN12-deficient cells are vulnerable to perturbation of mitotic regulators (related to Figure 3).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Table S2: Proteogenomic fold-change data (PTPN12 normal vs deficient) (related to Figure 2).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer
Table S2: Proteogenomic fold-change data (PTPN12 normal vs deficient) (related to Figure 2).